Radiofrequency Ablation for Osteoarthritis Post-Knee Replacement
(GRATKA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new method to manage ongoing knee pain after knee replacement surgery. It focuses on Genicular Radiofrequency Ablation (GRFA), which uses heat to target and numb specific knee nerves. The researchers aim to determine if this method can safely and effectively reduce pain for those who haven't found relief through treatments like physical therapy or medication. Suitable candidates for this trial had knee replacement surgery over a year ago and continue to experience significant knee pain despite trying other treatments. As an unphased trial, it offers patients the opportunity to explore innovative pain management solutions when other options have failed.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, since the trial is for those whose pain is not relieved by conventional treatments like medication, you might be able to continue them. It's best to discuss this with the trial coordinators.
What prior data suggests that genicular radiofrequency ablation is safe for patients with failed total knee arthroplasty?
Research shows that genicular radiofrequency ablation (GRFA) is generally safe for treating knee pain. Studies have found that it effectively reduces pain in people with knee osteoarthritis. Importantly, these studies found that GRFA is well-tolerated and rarely causes serious side effects, meaning most people do not experience harmful or uncomfortable reactions.
In these studies, patients did not report major negative effects from GRFA. This is encouraging for those considering the treatment, as safety remains a top priority. While this trial will be the first to specifically test GRFA's safety in patients who still experience pain after knee replacement surgery, existing research on GRFA suggests it could be a safe option for managing knee pain.12345Why are researchers excited about this trial?
Researchers are excited about Genicular Radiofrequency Ablation (GRFA) because it offers a novel approach to managing pain after knee replacement surgery in patients with osteoarthritis. Unlike traditional treatments such as medications or physical therapy, GRFA targets specific nerve branches directly, using heat generated by radiofrequency energy to disrupt pain signals. This method could provide longer-lasting pain relief without the systemic side effects associated with pain medications. Additionally, by precisely targeting nerves, GRFA may offer tailored pain management suited to individual anatomical differences, potentially enhancing its effectiveness.
What evidence suggests that genicular radiofrequency ablation is effective for post-knee replacement osteoarthritis?
Research has shown that genicular radiofrequency ablation (GRFA) effectively reduces knee pain for most people with osteoarthritis. GRFA uses heat to target specific nerves in the knee, helping to control pain. Many patients experience significant pain relief after this procedure. In this trial, participants will receive either GRFA or a sham procedure. GRFA has succeeded in providing pain relief and improved movement for those with chronic knee osteoarthritis who have not had surgery, as seen in previous studies. These findings suggest that GRFA could also be a promising option for those who still experience pain after knee replacement surgery.12467
Who Is on the Research Team?
Ashley Smith, PhD
Principal Investigator
University of Calgary
Are You a Good Fit for This Trial?
This trial is for individuals who had knee replacement surgery at least a year ago and still experience significant pain (more than 4/10) despite treatments like physiotherapy or medication. They must have had major pain relief from a specific diagnostic nerve block. Exclusions include uncontrolled bleeding disorders, pregnancy, severe psychiatric conditions, pacemakers, certain allergies, and other specific medical issues.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either thermal or sham genicular radiofrequency ablation (GRFA) for knee pain management
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at 3, 6, and 12 months post-GRFA
Crossover
Participants in the sham group are offered crossover to receive the active GRFA treatment
What Are the Treatments Tested in This Trial?
Interventions
- Genicular Radiofrequency Ablation
- Sham Genicular Radiofrequency Ablation
Genicular Radiofrequency Ablation is already approved in United States, European Union, Canada for the following indications:
- Chronic knee pain due to osteoarthritis
- Failed total knee arthroplasty
- Chronic knee pain due to osteoarthritis
- Chronic knee pain due to osteoarthritis
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Calgary
Lead Sponsor